IDO1 and neurodegenerative disease: In conclusion, inhibiting the kynurenine metabolic pathway is considered a potential therapeutic strategy, with inhibition of IDO1 activity being an important target for neuroprotective treatments to alleviate symptoms of neurodegenerative diseases and neuroinflammation.